Multiple Myeloma

P3, N=10000, Active, not recruiting, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Recruiting --> Active, not recruiting | N=7500 --> 10000 | Trial completion date: Jan 2027 --> Jun 2027 | Trial primary completion date: Jan 2027 --> Jun 2027

P1, N=280, Recruiting, Hangzhou DAC Biotechnology Co., Ltd. | N=110 --> 280 | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Jun 2027

The diagnosis was corroborated with further myeloma workup, which revealed an M band in serum electrophoresis, markedly elevated serum kappa free light chain, kappa:lambda ratio, and serum IgG. Diagnosis of PCM becomes challenging in atypical presentations, lacking classical morphology and immunophenotype, necessitating a comprehensive immunohistochemical panel and close clinicopathological correlation while accounting for lineage infidelity in poorly differentiated hematologic neoplasms to avoid diagnostic pitfalls.

P2/3, N=300, Recruiting, Peking University First Hospital | Not yet recruiting --> Recruiting

P1, N=50, Not yet recruiting, Peking University First Hospital

T cell-redirecting therapies represent a central pillar in modern oncology, delivering high response rates across hematologic malignancies with expanding roles in earlier treatment settings. Future progress will depend on improving durability, optimizing sequencing, mitigating toxicity, and enhancing real-world deliverability through next-generation and multitarget platforms.

At 1 year, he retained 20/20 vision, full extraocular motility, and no evidence of progression. This case highlights that even extensive orbital plasmacytoma may remain clinically silent and that prompt biopsy, staging, and radiotherapy can preserve excellent function.

While fludarabine and cyclophosphamide (Flu/Cy) remain the standard LD regimen, bendamustine has emerged as a potential alternative due to its distinct immunomodulatory properties and more favorable toxicity profile. However, the current evidence is largely derived from retrospective and non-randomized studies. Prospective, comparative trials are warranted to validate these findings and to better define the optimal LD strategy across disease types and CAR-T platforms.

P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Aug 2027

P3, N=386, Completed, Celgene | Active, not recruiting --> Completed | Trial completion date: Apr 2027 --> Apr 2026 | Trial primary completion date: Apr 2027 --> Apr 2026

This study successfully identified and validated NETs-related biomarkers for MM through machine learning and experimental validation. Understanding the role of NETs-related biomarkers in MM could not only deepen our understanding of the disease but also offer information for clinical applications.

Moreover, DDR-associated vulnerabilities provide opportunities for precision therapies, including PARP inhibitor-based synthetic lethality strategies. This review summarizes the mechanistic and clinical significance of germline DDR alterations in MM and highlights their translational potential in precision oncology.